Sex specific analysis of patients with and without reported statin intolerance referred to a specialized outpatient lipid clinic.


Journal

Biology of sex differences
ISSN: 2042-6410
Titre abrégé: Biol Sex Differ
Pays: England
ID NLM: 101548963

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 16 02 2024
accepted: 19 08 2024
medline: 3 9 2024
pubmed: 3 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

Lowering LDL-cholesterol is a fundamental goal for both primary and secondary prevention of atherosclerotic cardiovascular diseases. Our study aims to analyse potential sex disparities regarding the tolerability and effectiveness of lipid-lowering therapy in patients with and without reported statin intolerance who are being treated at a lipid-outpatient clinic. From 2017 to 2022, n = 1062 patients (n = 612 men, n = 450 women) at high-risk were referred to our lipid-outpatient clinic because of difficulties in lipid control by primary healthcare providers. The main therapeutic objective was to optimize lipid-lowering therapy according to current treatment guidelines. Patients presented with high LDL-C baseline levels (4.97 ± 1.81 mmol/l (192 ± 70 mg/dL) in men and 5.46 ± 2.04 mmol/l (211 ± 79 mg/dL) in women). Intolerance towards statins was reported more frequently by women (48.2%) than by men (38.9%, p = 0.004). LDL-C continuously decreased with individual treatment adjustments across follow-up visits. In total, treatment goals (LDL < 1.4 mmol/l (< 55 mg/dl) or < 1.8 mmol/l (< 70 mg/dl)) were accomplished in 75.8% of men and 55.5% of women after the last follow-up visit (p < 0.0001). In men, these data are almost identical in subjects with statin intolerance. In contrast, treatment goals were reached less frequently in women with statin intolerance compared to women tolerant to statin therapy. Even if treated in a specialized lipid clinic, women are less likely to reach their target LDL-C than men, particularly when statin intolerant. Nevertheless, many patients with statin intolerance can be successfully treated using oral combination and PCSK9 inhibitor therapy. However, ongoing follow-up care to monitor progress and to adjust treatment plans is necessary to reach this goal. We investigated patients at high cardiovascular risk who were referred to our specialized lipid outpatient clinic because of elevated lipid levels and difficulties in lipid-lowering treatment in the primary care setting. The primary goal of such a clinic is to help patients to achieve optimal lipid levels through personalized treatment plans. We focused on prescription behavior and differences in treatment tolerability and effectiveness between men and women.A large proportion of patients (more frequently women (48.2%) than men (38.9%)) reported intolerance towards statins and most patients’ LDL-cholesterol levels were far away from treatment goals. However, when treated at a specialized lipid clinic providing ongoing follow-up care to monitor progress and to adjust treatment plans if necessary, many of those patients were able to tolerate lipid lowering medication to achieve better lipid control and to maintain their lipid levels within target ranges.However, women were less likely to reach LDL-cholesterol treatment targets compared to men, especially if they reported intolerance towards statins. Ongoing follow-up care to monitor progress and to adjust treatment plans is necessary to reach treatment goals.

Sections du résumé

BACKGROUND BACKGROUND
Lowering LDL-cholesterol is a fundamental goal for both primary and secondary prevention of atherosclerotic cardiovascular diseases. Our study aims to analyse potential sex disparities regarding the tolerability and effectiveness of lipid-lowering therapy in patients with and without reported statin intolerance who are being treated at a lipid-outpatient clinic.
METHODS METHODS
From 2017 to 2022, n = 1062 patients (n = 612 men, n = 450 women) at high-risk were referred to our lipid-outpatient clinic because of difficulties in lipid control by primary healthcare providers. The main therapeutic objective was to optimize lipid-lowering therapy according to current treatment guidelines.
RESULTS RESULTS
Patients presented with high LDL-C baseline levels (4.97 ± 1.81 mmol/l (192 ± 70 mg/dL) in men and 5.46 ± 2.04 mmol/l (211 ± 79 mg/dL) in women). Intolerance towards statins was reported more frequently by women (48.2%) than by men (38.9%, p = 0.004). LDL-C continuously decreased with individual treatment adjustments across follow-up visits. In total, treatment goals (LDL < 1.4 mmol/l (< 55 mg/dl) or < 1.8 mmol/l (< 70 mg/dl)) were accomplished in 75.8% of men and 55.5% of women after the last follow-up visit (p < 0.0001). In men, these data are almost identical in subjects with statin intolerance. In contrast, treatment goals were reached less frequently in women with statin intolerance compared to women tolerant to statin therapy.
CONCLUSION CONCLUSIONS
Even if treated in a specialized lipid clinic, women are less likely to reach their target LDL-C than men, particularly when statin intolerant. Nevertheless, many patients with statin intolerance can be successfully treated using oral combination and PCSK9 inhibitor therapy. However, ongoing follow-up care to monitor progress and to adjust treatment plans is necessary to reach this goal.
We investigated patients at high cardiovascular risk who were referred to our specialized lipid outpatient clinic because of elevated lipid levels and difficulties in lipid-lowering treatment in the primary care setting. The primary goal of such a clinic is to help patients to achieve optimal lipid levels through personalized treatment plans. We focused on prescription behavior and differences in treatment tolerability and effectiveness between men and women.A large proportion of patients (more frequently women (48.2%) than men (38.9%)) reported intolerance towards statins and most patients’ LDL-cholesterol levels were far away from treatment goals. However, when treated at a specialized lipid clinic providing ongoing follow-up care to monitor progress and to adjust treatment plans if necessary, many of those patients were able to tolerate lipid lowering medication to achieve better lipid control and to maintain their lipid levels within target ranges.However, women were less likely to reach LDL-cholesterol treatment targets compared to men, especially if they reported intolerance towards statins. Ongoing follow-up care to monitor progress and to adjust treatment plans is necessary to reach treatment goals.

Autres résumés

Type: plain-language-summary (eng)
We investigated patients at high cardiovascular risk who were referred to our specialized lipid outpatient clinic because of elevated lipid levels and difficulties in lipid-lowering treatment in the primary care setting. The primary goal of such a clinic is to help patients to achieve optimal lipid levels through personalized treatment plans. We focused on prescription behavior and differences in treatment tolerability and effectiveness between men and women.A large proportion of patients (more frequently women (48.2%) than men (38.9%)) reported intolerance towards statins and most patients’ LDL-cholesterol levels were far away from treatment goals. However, when treated at a specialized lipid clinic providing ongoing follow-up care to monitor progress and to adjust treatment plans if necessary, many of those patients were able to tolerate lipid lowering medication to achieve better lipid control and to maintain their lipid levels within target ranges.However, women were less likely to reach LDL-cholesterol treatment targets compared to men, especially if they reported intolerance towards statins. Ongoing follow-up care to monitor progress and to adjust treatment plans is necessary to reach treatment goals.

Identifiants

pubmed: 39223591
doi: 10.1186/s13293-024-00642-y
pii: 10.1186/s13293-024-00642-y
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Cholesterol, LDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67

Informations de copyright

© 2024. The Author(s).

Références

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
doi: 10.1093/eurheartj/ehx144 pubmed: 28444290 pmcid: 5837225
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2018;2019(139):e1082–143.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.
doi: 10.1093/eurheartj/ehz455 pubmed: 31504418
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and Cardiovascular Risk Reduction among different therapeutic interventions: a systematic review and Meta-analysis. JAMA. 2016;316:1289–97.
doi: 10.1001/jama.2016.13985 pubmed: 27673306
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
doi: 10.1016/S0140-6736(10)61350-5 pubmed: 21067804
Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8:36–49.
doi: 10.1016/S2213-8587(19)30388-2 pubmed: 31862150
Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.
doi: 10.1016/S0140-6736(12)60367-5 pmcid: 3437972
Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637–43.
doi: 10.1016/S0140-6736(20)32332-1 pubmed: 33186535 pmcid: 8015314
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22.
doi: 10.1056/NEJMoa1615664 pubmed: 28304224
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.
doi: 10.1056/NEJMoa1801174 pubmed: 30403574
Sayed A, Shazly O, Slipczuk L, Krittanawong C, Baloch F, Virani SS. The clinical efficacy and safety of Bempedoic Acid in patients at elevated risk of Cardiovascular Disease: a Meta-analysis of Randomized clinical trials. Cardiovasc Drugs Ther. 2023.
Cholesterol Treatment Trialists’ (CTT), Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–405.
doi: 10.1016/S0140-6736(14)61368-4
Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017;6:e006901.
doi: 10.1161/JAHA.117.006901 pubmed: 29151034 pmcid: 5721774
Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–89.
doi: 10.1093/eurjpc/zwaa047 pubmed: 33580789
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46.
doi: 10.1016/j.atherosclerosis.2019.03.014 pubmed: 31054483
Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79:1802–13.
doi: 10.1016/j.jacc.2022.02.048 pubmed: 35512860 pmcid: 9344279
Cannon CP, De Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a Registry of patients with atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6:1060.
doi: 10.1001/jamacardio.2021.1810 pubmed: 34132735
Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis. 2017;266:158–66.
doi: 10.1016/j.atherosclerosis.2017.08.013 pubmed: 29028484
Ellins EA, Harris DE, Lacey A, Akbari A, Torabi F, Smith D, et al. Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: influence of depression and sex. PLoS ONE. 2022;17:e0264529.
doi: 10.1371/journal.pone.0264529 pubmed: 35213664 pmcid: 8880762
Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, et al. Age- and gender-related differences in LDL-Cholesterol Management in outpatients with type 2 diabetes Mellitus. Int J Endocrinol. 2015;2015:957105.
doi: 10.1155/2015/957105 pubmed: 25873960 pmcid: 4383267
Schoen MW, Tabak RG, Salas J, Scherrer JF, Buckhold FR. Comparison of adherence to Guideline-based cholesterol treatment goals in men Versus Women. Am J Cardiol. 2016;117:48–53.
doi: 10.1016/j.amjcard.2015.10.007 pubmed: 26589821
De Smedt D, De Bacquer D, De Sutter J, Dallongeville J, Gevaert S, De Backer G, et al. The gender gap in risk factor control: effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol. 2016;209:284–90.
doi: 10.1016/j.ijcard.2016.02.015 pubmed: 26913370
Kim B-K, Hong S-J, Lee Y-J, Hong SJ, Yun KH, Hong B-K, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380–90.
doi: 10.1016/S0140-6736(22)00916-3 pubmed: 35863366
Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603.
doi: 10.1177/2047487319864671 pubmed: 31357887
Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122–8.
doi: 10.1016/j.atherosclerosis.2020.12.023 pubmed: 33514449
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372:2387–97.
doi: 10.1056/NEJMoa1410489 pubmed: 26039521
Aygun S, Tokgozoglu L. Comparison of Current International guidelines for the management of Dyslipidemia. J Clin Med. 2022;11:7249.
doi: 10.3390/jcm11237249 pubmed: 36498823 pmcid: 9737468
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.
doi: 10.1016/S0140-6736(16)31357-5 pubmed: 27616593
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence with mortality in patients with atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4:206–13.
doi: 10.1001/jamacardio.2018.4936 pubmed: 30758506 pmcid: 6439552
Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42:243–52.
doi: 10.1093/eurheartj/ehaa1011 pubmed: 33367526
Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–25.
doi: 10.1093/eurheartj/ehz458 pubmed: 31362307 pmcid: 6855142
Jeong HY, Lee S-Y, Kim SH, Kim J. Long-term benefit and Withdrawal Effect of statins after Percutaneous Coronary intervention: a Nationwide Population-based Cohort Study. Patient Prefer Adherence. 2020;14:717–24.
doi: 10.2147/PPA.S245324 pubmed: 32308376 pmcid: 7147626
Thompson W, Morin L, Jarbøl DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin Discontinuation and Cardiovascular events among older people in Denmark. JAMA Netw Open. 2021;4:e2136802.
doi: 10.1001/jamanetworkopen.2021.36802 pubmed: 34854906 pmcid: 8640890
Bruckert E, Parhofer K, Georg et al. Gonzalez- Juanatey, Jose Ramon, Nordestgard, Børge, Arca, Marcello, Giovas, Periklis,. Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Advances in Therapy. 2020;37:1724–36.
Vynckier P, Ferrannini G, Rydén L, Jankowski P, De Backer T, Gevaert S, et al. Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. Eur J Prev Cardiol. 2022;29:344–51.
doi: 10.1093/eurjpc/zwaa144 pubmed: 33624111
Allahyari A, Jernberg T, Hagström E, Leosdottir M, Lundman P, Ueda P. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41:3900–9.
doi: 10.1093/eurheartj/ehaa034 pubmed: 32072178 pmcid: 7654933
Bradley CK, Wang TY, Li S, Robinson JG, Roger VL, Goldberg AC, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry. J Am Heart Assoc. 2019;8:e011765.
doi: 10.1161/JAHA.118.011765 pubmed: 30913959 pmcid: 6509731
Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213–23.
doi: 10.1093/eurheartj/ehac015 pubmed: 35169843 pmcid: 9757867
Bair TL, May HT, Knowlton KU, Anderson JL, Lappe DL, Muhlestein JB. Predictors of statin intolerance in patients with a new diagnosis of atherosclerotic Cardiovascular Disease within a large Integrated Health Care Institution: the IMPRES Study. J Cardiovasc Pharmacol. 2020;75:426–31.
doi: 10.1097/FJC.0000000000000808 pubmed: 32079856
Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165:665–78. 678.e1.
doi: 10.1016/j.ahj.2013.02.011 pubmed: 23622903
Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex differences in the Use of statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019;12:e005562.
doi: 10.1161/CIRCOUTCOMES.118.005562 pubmed: 31416347 pmcid: 6903404
Skilving I, Eriksson M, Rane A, Ovesjö M-L. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. Eur J Clin Pharmacol. 2016;72:1171–6.
doi: 10.1007/s00228-016-2105-2 pubmed: 27484241 pmcid: 5021730

Auteurs

Maximilian A Muck (MA)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Marcus Fischer (M)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.
Caritas Krankenhaus St. Lukas, Kelheim, 93309, Germany.

Michael Hamerle (M)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Christina Strack (C)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Maxime Holzhaeuer (M)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Dennis Pfeffer (D)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Ute Hubauer (U)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Lars S Maier (LS)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany.

Andrea Baessler (A)

Klinik und Poliklinik für Innere Medizin 2, University of Regensburg, Regensburg, Germany. andrea.baessler@ukr.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH